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Gain of function (GOF) DNA binding domain (DBD) mutations of TP53 upregulate chromatin
regulatory genes that promote genome-wide histone methylation and acetylation. Here, we
therapeutically exploit the oncogenic GOF mechanisms of p53 codon 158 (Arg158) mutation,
a DBD mutant found to be prevalent in lung carcinomas. Using high throughput compound
screening and combination analyses, we uncover that acetylating mutp53R158G could render
cancers susceptible to cisplatin-induced DNA stress. Acetylation of mutp53R158G alters DNA
binding motifs and upregulates TRAIP, a RING domain-containing E3 ubiquitin ligase which
dephosphorylates IĸB and impedes nuclear translocation of RelA (p65), thus repressing
oncogenic nuclear factor kappa-B (NF-ĸB) signaling and inducing apoptosis. Given that this
mechanism of cytotoxic vulnerability appears inapt in p53 wild-type (WT) or other hotspot
GOF mutp53 cells, our work provides a therapeutic opportunity specific to Arg158-mutp53
tumors utilizing a regimen consisting of DNA-damaging agents and mutp53 acetylators,
which is currently being pursued clinically.
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T P53 missense mutations are among the most commongenetic lesions in tumors1, which often coincide with theearlier onset of oncogenesis than patients with p53 loss2.
A single nucleotide substitution at the DNA-binding domain
(DBD) renders the protein defective in DNA-binding, loss of
tumor suppressive properties and concomitantly prevents the
negative feedback regulation through MDM23,4, leading to mas-
sive accumulation of full length mutant p53 (mutp53). Growing
evidence from recent studies suggest that cells with prevalent
mutp53 acquire additional oncogenic gain-of-function (GOF)
based on their unique structural modifications5–8. Depletion of
mutp53 or inhibition of its co-activator have demonstrated strong
cytotoxicity in tumor cells6,9,10.
Proposed oncogenic mechanisms of hotspot p53 mutations
include prolonged tumor necrosis factor alpha (TNF-α) signaling
through the activation of NFĸB (nuclear factor kappa-light-
chain-enhancer of activated B cells)11,12, causing chronic tumor-
associated inflammation, as well as altered structural interaction
between mutated p53 and DNA that induces transcriptional
perturbations to promote tumor-associated gene expression13–15.
Data derived from The Cancer Genome Atlas (TCGA)
reveal a specific point mutation on arginine codon 158 (ArgR158)
to be a recurrent mutation in lung carcinomas (16 out of
742 specimens)16–19. In contrast to the other well-established
hotspot mutp537,8,20–23, the functional aspects of this mutation
have not been well-characterized.
In this study, we uncover a mechanism of activating mutp53-
dependent apoptotic function in cancer cells through p53R158G
acetylation, and demonstrate that TRAIP regulation of NFĸB is
the main molecular driver underpinning this observed sensitivity.
We further show in a high-throughput screen that acetylation of
p53R158G can be achieved with several pharmacologic agents,
providing a cogent basis for further clinical development.
Results
GOF p53R158G confers differential drug sensitivity. Among the
TP53 mutations found in ~50% of non-small cell lung cancer24,
p53R158G/H/L is one of the most common mutation hotspots
according to multiple public databases (TCGA, COSMICS, IARC
p53 Database), despite being reported in different frequencies25.
Further TCGA analysis on sequencing of 742 lung cancer patients
showed a frequency of 4.5% (n= 8) and 1.4% (n= 8) in LUSC
(n= 178) and adenocarcinoma (LUAD, n= 564) subtypes,
respectively (Supplementary Fig. 1A, Supplementary Table 1). In
addition, the frequency of codon 158 was found to be comparable
to other hotspot mutp53 in both lung cancer subtypes (Supple-
mentary Table 2). H2170 LUSC cells that are homozygous for
p53R158G (Supplementary Fig. 1B) demonstrated impaired
MDM2 and CDKN1A transactivation when treated with Nutlin-
3a, a MDM2 antagonist, as compared to MRC5 (p53wt) cells,
indicating loss of p53 function (Supplementary Fig. 1I). To gain
better insights into the p53R158G function, we generated isogenic
cell-lines expressing either wild-type (p53wt) or mutant
(p53R158G) p53 from homozygous deleted LUSC Calu-1 cells
(p53−/−). As forced expression of WT p53 could induce cyto-
toxicity, we verified the presence of full length TP53 in each
isolated stable clones (Supplementary Fig. 1C–H). As expected,
expression of wild-type p53 (wtp53) increased transcription of
MDM2, CDKN1A, PUMA, and PMAIP1 transcripts compared to
p53−/− cells; in p53R158G cells, elevated CDKN1A showed partial
preservation of p53 function, but reduced PMAIP1 transcription
indicated gain of alternative function (Supplementary Fig. 1J–M).
Functionally, mutp53R158G overexpression significantly increased
cellular motility (Fig. 1a, b) as well as anchorage-independent
colony formation (Fig. 1e, f); whereas invasiveness of H2170 cells
could be reduced with TP53 knockdown (Fig. 1c, d). In contrast,
overexpression of wtp53 exerted strong tumor suppressive effects
in Calu-1 cells by reducing invasiveness (Fig. 1a, b) with no
apparent colony growth. Importantly, xenograft tumors derived
from p53R158G cells demonstrated more aggressive growth rela-
tive to those from p53−/− and p53wt cells (Fig. 1g, h), consistent
with the oncogenic GOF described in other hotspot
variants10,22,26.
Understanding the mechanisms underlying mutp53 GOF has
allowed for anti-tumoral strategies aimed at inhibiting the
oncogenic attributes of mutp536,9,10,27–29. Accordingly, we
screened isogenic Calu-1 cell-lines through high-content com-
pound screening (Supplementary Table 3), and quantifying the
relative cell viability after single drug treatment at 0.1 or 1 µM,
respectively. We first selected for compounds that showed efficacy
(> 50% growth inhibition) in at least one cell type (Supplemen-
tary Table 3), and identified inhibitors specific to p53−/−, p53wt,
and p53R158G cell-lines (Fig. 2a, Supplementary Fig. 2A, B). Loss
of p53 was found to confer sensitivity to paclitaxel as suggested
previously (Supplementary Fig. 2A)30. Interestingly, 17 com-
pounds demonstrated selective sensitivity in p53R158G cells
compared with wtp53 and null cells (Fig. 2a, Supplementary
Fig. 2A, B). Among these, potent inhibitory effects (10-fold
differences in ED50 values) against p53R158G cells were confirmed
in bleomycin, AZD7762, cladribine, topotecan, nocodazole,
volasertib, 17-AAG, belinostat (PXD101), bosutinib, and JQ1
using dose-response evaluation (Supplementary Fig. 2C). Con-
sistent with previous reports9,10,31, inhibitors of HSP90, histone
deacetylase (HDAC) and polo-like kinase (PLK) demonstrated
selective activity against mutp53 cells.
HDAC inhibitors have demonstrated synergistic activities
through epigenetic mechanisms with a variety of clinically
approved agents in several cancers. Accordingly, the clinically
approved belinostat32 was selected to delineate the underlying
mechanism conferring sensitivity to mutp53. We performed a
combination screening on belinostat with cisplatin, a DNA-
damaging cytotoxic agent that forms the backbone of chemother-
apy against metastatic SCC. In this context, the cell viability (%)
and combinatorial score of a belinostat/cisplatin combination was
quantified in our study models (Fig. 2b, c). The combination was
antagonistic on p53wt cells (Bliss value > 0), possibly due to
concurrent activation of cell cycle checkpoints33,34. In contrast,
profound synergistic response was observed in p53R158G cells
(Bliss value < 0) when combining belinostat (0.1 µM) with
cisplatin (0.1–10 µM), indicating that the observed cell response
was greater than the predicted values (Fig. 2c). Concomitantly,
while belinostat lowered cisplatin IC50 in mutp53R158G Calu-1
cells, it had little effect on cell-lines with wild-type or null
p53 status (Fig. 2d). The enhanced cytotoxicity was validated in
H2170 cells, with belinostat augmenting cisplatin-induced
caspase 3 and PARP cleavage (Fig. 3a). The fold increase of
cleaved PARP and caspase 3 were compared across cisplatin
treatment and cisplatin/belinostat combination to indicate
presence of synergy (Fig. 3b). Interestingly, similar observation
was observed in other cancer types harboring Arg158 p53
mutations, including H441 (lung adenocarcinoma, p53R158L),
H661 (lung large cell carcinoma, p53R158L), and H747 (colorectal
carcinoma, p53R158L) (Fig. 3a, b). On the contrary, cancer cells
expressing other hotspot GOF p53 mutations, such as LUSC cells
H596 (p53G245C) and ChaGo-k-1 (p53C275F); lung adenocarci-
noma H1417 (p53R175L) and H1975 (p53R273H); breast carci-
noma SK-BR-3 (p53R175H), HCC70 (p53R248Q), BT-549
(p53R249S) and MDA-MB-468 (p53R273H); pancreatic carcinoma
MIA-Paca-2 (p53R248W) and PANC-1 (p53R273H); did not
show increased in apoptotic markers when belinostat was
combined with cisplatin (Fig. 3b, Supplementary Fig. 3A, B).
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Similar lack of synergism was observed in other lung cancer cells
with p53 deletion (Calu-1), point-nonsense mutation (H520, SK-
MES-1) and wild-type p53 (A549) (Fig. 3b, Supplementary
Fig. 3A). These findings indicate specific mechanistic under-
pinnings of the observed synergy in Arg158 mutp53 cells.
Acetylation of mutp53R158G induced pro-apoptotic phenotype.
As HDAC inhibitors can acetylate histones and other cellular
proteins, possible mechanisms that modulate mutp53 function
include Lysine acetylation of histones affecting DNA configura-
tion favoring mutp53 access to DNA-binding elements, or direct
modification of mutp53 itself leading to alternative DNA binding.
To evaluate this, we first demonstrated that a low, sub-cytotoxic
concentration of belinostat (0.1 µM) was sufficient to acetylate
both H3 and H4 (Fig. 3c) in H2170 cells, and was synergistic with
cisplatin in apoptotic assays (Fig. 3d, f–h; Supplementary Fig. 3C,
D). The transcriptional regulation of p53 targets (CDKN1A,
PUMA, PMAIP1, BAX) and Bcl-2 family members (BCL2, BAD,
BAK1) strongly implicated p53 transcriptional regulation in this
observed synergy with DNA-damaging cisplatin (Fig. 3j, k). The
dependence on mutp53R158G, functioning through active tran-
scription regulation, was further substantiated by the positive
p53-reporter-luciferase activity of combination drug-treatment
(Supplementary Fig. 4A). In addition, DNA-binding affinity of
mutp53 was validated with gel retardation assay, with wtp53 and
mutp53 showing comparable binding affinity to a 31-bp p53
response element sequence from CDKN1A (Supplementary
Fig. 4B, C). Consistently, depletion of p53 from H2170 parental
cells with different short hairpin (shRNA) constructs or small
interfering RNA (siRNA) reduced PARP and caspase 3 cleavage
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Fig. 1 Mutation at Arg158 is a GOF p53 isoform. a–d Cell invasion assays were performed on isogenic Calu-1 cells (p53−/−, p53wt and mutp53R158G) and
H2170 cells. Cells seeded in Matrigel invasion chambers were fixed and stained at the indicated time point. Representative images were shown for Calu-1
clones (n= 3 independent experiments) (a) and H2170 cells with Scr of TP53 siRNA knockdown (n= 2 independent experiments) (c). Immunoblots
verifying p53 knockdown are shown on the right. The number of cells in four random microscopic fields ×4 were quantified for Calu-1 (b) and H2170 (d)
cells. Data are expressed as mean ± SD. 50 nM of siRNA used per transfection. Two tailed Student’s t-test; *P < 0.05. Scale bar, 200 µm. e, f Anchorage-
independent colony forming assays were performed on isogenic Calu-1 cells (p53−/− and five independent mutp53R158G clones). Representative images of
colony formation for each cell type, stained with MTT at assay endpoint (e). The number of colonies were quantified (f) and expressed as mean of
triplicates ± SD (n= 3 independent experiments). Two tailed Student’s t-test; *P < 0.05. g, h In vivo growth rates of p53−/−, p53wt, p53R158G cells were
measured upon day of implantation and monitored over time (g). Images shown are representative tumor sizes at assay endpoint (h). Tumor sizes are
presented as mean ± SEM (n= 5 animals). Two-way ANOVA with Bonferroni correction; *P < 0.05; **P < 0.01; ***P < 0.001.
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(Supplementary Fig. 4D). Apoptosis induced by the combination
treatment was significantly abrogated in the shp53 cells (Sup-
plementary Fig. 4E). Logically, destabilization and depletion of
GOF mutp53 explains potent anti-tumor cytotoxicity9,10, but
paradoxically, we observed no reduction of mutp53R158G in
H2170 cells despite robust apoptosis (Fig. 3e). Rather, analyses of
the post-translational modifications (PTM) of p53 showed that
while cisplatin dose-dependently increased p53 phosphorylation
and acetylation, combination with belinostat potentiated only its
acetylation (Fig. 3e).
To establish the role of p53R158G in promoting apoptosis, we
conducted synonymous experiments using isogenic Calu-1 cell-
lines. Cisplatin alone and in combination with belinostat
triggered comparable S-phase arrest regardless of the p53 status,
suggesting that the synergy is independent of its cytostatic effect
(Figs. 3i, 4c). Cisplatin alone induced pronounced apoptotic
response in both p53wt and p53R158G cells, however, enhanced
cytotoxicity and p53 acetylation by belinostat were restricted to
p53R158G cells (Fig. 4a, b, d), which is concordant with the IC50
values (Fig. 2d). Transcriptional activation of MDM2 was only
observed in wtp53 but not mutp53 or null cells (Fig. 4e); whereas,
CDKN1A, PUMA, and BAX were induced post-treatment in
mutp53 but not null cells (Fig. 4f–i), implicating p53R158G in the
synergistic pro-apoptotic effect.
To investigate the role of p53 acetylation in mediating the pro-
apoptotic function of mutp53, we first constructed p53R158G
mutants by substituting the Lysine residues at the DBD
(p53R158G(DBD, K-A)), C-terminal domain (p53R158G(CT, K-A)) or
the whole protein (p53R158G(K20A)). Expectedly, these modifications
were unable to overcome cell death induced by single agent
cisplatin, which could occur via the p53-independent extrinsic
apoptotic pathway35. Nonetheless, belinostat-induced synergy was
abrogated in p53R158G(DBD, K-A) and p53R158G(K20A) cells (Fig. 4a,
b, d), both cell types with impaired Lysine acetylation at the p53
DBD. In contrast, the synergistic effect was maintained in p53R158G
(CT,K-A) clones (Fig. 4b), suggesting that C-terminal acetylation is
not involved in mutp53-effected cytotoxicity.
To compare the impact of acetylation and phosphorylation on
p53R158G-dependent apoptosis, we conducted high-content
immunofluorescence imaging to detail the post-translational
events in individual nuclei (Fig. 4j), and two key observations
were made. Firstly, single treatment of belinostat and cisplatin
increased the acetylated-p53 population (Q4), with the combina-
tion treatment further augmented cells in Q4 (Supplementary
Fig. 5A, C). Secondly, cisplatin but not belinostat treatment
strongly increased the phosphorylated-p53-labelled cell popula-
tion (Q3), and combination treatment had no effect on cells in Q3
(Supplementary Fig. 5B, D). This data demonstrated the positive
correlation of acetylated p53R158G with combination treatment,
which significantly triggered cellular apoptosis. To further validate
the importance of p53R158G acetylation, isogenic p53 cell-lines
were treated with tenovin-6, a potent sirtuin inhibitor and known
acetylator of p5336. While p53-expressing cells were more sensitive
to tenovin-6 (Fig. 4k), acetylation of p53R158G increased cleavage
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Fig. 2 High-content screening reveals compounds selective for p53R158G cells. a High-content screening of anti-cancer compounds and epigenetic
modulators on p53 clones. The efficacy of the tested compounds was quantified relative to the mean viability of vehicle-treated cells (384-well format, in
triplicates) 72 h post-treatment (n= 1). Heatmap shows compounds filtered for specificity to p53R158G cells (growth inhibition > 50% in p53R158G; <50% in
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vehicle control (b). Data are presented as mean cell viability (n= 3 independent experiments). Viability response of belinostat/cisplatin combination from
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Data are represented as mean IC50 ± SD (n= 3 independent experiments). Two tailed Student’s t-test; *P < 0.05.
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of PARP and caspase 3 (Fig. 4l). Collectively, acetylation of the
DBD is crucial to effecting apoptosis by mutp53R158G.
Mutp53R158G binds to distinct DNA sequence motifs. We
postulated that mutp53R158G binds to and activates a distinct
spectrum of chromatin regulatory genes from wtp53, which may
be significantly altered by drug-induced acetylation. Firstly, state-
of-the-art molecular modelling and simulation studies were per-
formed to compare the structural dynamics of wild-type p53,
mutp53R158G and acetylated-mutp53R158G using monomers of
the respective DBD. The loss of the R158 sidechain creates a large
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cavity that changes the structure of the DBD – most notable is the
loss of the stability of helix H1, which is responsible for dimer
formation of activated p53 (Supplementary Fig. 6A, C)—that
could likely disrupt key interactions between the DBD (K120,
R280, R248) and DNA. Interestingly, acetylation of the Lysine
residues within the DBD reduces the sidechain positive charges,
resulting in structural and chemical alterations, which suggest
restoration of the dimerization capacity of the core domain of
mutp53R158G (Supplementary Fig. 6B, D). While the key inter-
actions of K120 with the major groove of the DNA remain
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impaired in the acetylated R158G mutant, it is compensated for by
the interactions between acetylated K201 and the minor groove
(Supplementary Fig. 6D). The most intriguing alteration in the
acetylated R158G mutant is an increase in the length of the
dimerization helix H1 from R181 to D186—about 1.5 extra turns
of a helix—that will promote the formation of a dimer that is more
stable than the WT and is also associated with the introduction of
two salt bridges across the dimer interface (E180 of each monomer
forms a salt bridge with R181 of the second monomer; Supple-
mentary Fig. 6D). We speculate that this may increase DNA
binding and result in the enhanced transcription activity seen in
the acetylated mutp53R158G. The simulations also highlighted the
formation of key stabilizing interactions between the polar groups
introduced by the acetylated K101 and K164 that stabilize the
overall conformation of the mutp53. This supports our earlier
observations that conversions of these two Lysines to Alanines in
the DBD (p53R158G(DBD,K-A)) resulted in attenuation of the pro-
apoptotic activity seen in acetylated R158G (Fig. 4a, b, d).
Next, we compared the DNA-binding sequences and tran-
scriptional targets of vehicle- and drug-treated p53wt and
p53R158G cells through p53 chromatin immunoprecipitation
(ChIP) followed by sequencing (ChIP-Seq). In untreated cells,
both wtp53 and mutp53 bound significantly to the proximal
regions (within 1 kb) of the transcription start sites (TSS) (Fig. 5a,
Supplementary Fig. 7A). Drug treatment led to marked increase
in genomic binding in both p53R158G and p53wt cells, with higher
signal intensity around the TSS-proximal regions (Fig. 5a,
Supplementary Fig. 7A), suggestive of DNA-binding capability
of both p53 isoforms. Importantly, predicted motif analysis for
TSS-proximal peaks suggested that p53 consensus motifs were
enriched not just in p53wt but also in p53R158G (motif similarity
P= 0.029 and 0.039, TOMTOM match statistic; P= 1 × 10−16
and 1 × 10−265, HOMER statistic) (Fig. 5a, Supplementary
Fig. 7A). However, by comparing the binding patterns of wtp53
and mutp53 to TSS, we found that the mutp53R158G peaks were
highly dissimilar from the peaks of wtp53 (Supplementary Fig. 8,
column 1 row 3). In addition, we aligned the ChIP-seq data from
the cells treated with the belinostat/cisplatin combination, and
showed that TSS-proximal peaks post-treatment were distinct
from the vehicle control in both wtp53 and mutp53. Interestingly,
peaks enriched in drug-treated mutp53R158G cells resembled that
of drug-treated wtp53 (Supplementary Fig. 8, column 2 row 4).
These data collectively suggest that mutp53R158G partially retains
wtp53 activity when cells are exposed to stress signal, which
supports the induction of wtp53 response genes by the drug-
induced transactivation of p53R158G in H2170 cells (Supplemen-
tary Fig. 4A), as well as the increased DNA-binding affinity of
mutp53 upon acetylation (Supplementary Fig. 4B, C).
To identify the genes activated by acetylated p53R158G which
are associated with the induction of apoptosis, we compared the
treatment-induced perturbations of transcriptomic profiles (by
Ampliseq RNA sequencing) between wild-type and mutant cells.
These gene panels were subjected to KEGG ontogeny enrichment
analysis. Expectedly, genes mediating p53 signaling were elevated
in p53wt cells after treatment (P-value= 7.87 × 10−11); in
p53R158G, genes associated with cell cycle, DNA replication and
DNA damage repair pathways were prioritized (Supplementary
Fig. 7B). We further analyzed gene sets obtained from both ChIP-
seq and AmpliSeq for concordance of significantly perturbed
genes pre- and post-treatment (log2 > 1.5), also found to be bound
by p53 within the proximal regions (<10 kb from TSS), as direct
p53 targets (Fig. 5b, Supplementary Table 4). Selected genes were
validated with qPCR, and consistently, direct p53wt binding
increased expression of canonical p53 downstream genes
(MDM2, GADD45A, PMAIP1) (Supplementary Fig. 7C-E, I-K).
Among the mutp53-bound target genes, TRAIP and RAD51 were
markedly induced (log2-fold= 2.72 and 2.767, respectively) after
drug treatment relative to wild-type cells (Supplementary Table 4,
Fig. 5c, d, Supplementary Fig. 7F, L). Work on other p53 hotspot
mutants have described part of the mechanistic basis for mutp53’s
GOF as direct interaction with E26 transformation-specific (ETS)
motifs37. Two chromatin regulatory genes downstream of ETS2,
KMT2D, and KAT6A22, reported to be positively associated
with hotspot GOF mutp53 (R175H, R248Q, R248W, R249S, or
R273H), were neither transactivated nor upregulated in p53R158G
(Fig. 5f, g, Supplementary Fig. 7G, H), thereby distinguishing
DNA binding by Arg158 mutants from other mutated p53 GOF
isoforms.
RAD51 and TRAIP are key components of the DNA damage
and repair mechanisms38–40. However, combination-treated
p53R158G cells did not demonstrate increased DNA damage
response when compared to p53 loss or wtp53 cells, based on the
analysis of induced-γH2AX (Fig. 5h), a surrogate marker for
DNA damage, and the quantification of broken DNA measured
using comet tail length (Supplementary Fig. 9A, B). Therefore, it
is unlikely that the enhanced cytotoxicity in p53R158G is due to
altered DNA damage signaling. We postulated that NFĸB
pathway regulation by TRAIP, a RING domain-containing E3
ubiquitin ligase41, may explain the altered mutp53 function, as
TRAIP is known to suppress NFĸB42–45. We showed that TRAIP
upregulation in p53R158G cells correlated with the IĸB depho-
sphorylation and stabilization (Fig. 5h). Active IĸB inhibits NFĸB
through blocking the nuclear import of p6546. Accordingly, we
hypothesize that acetylation of p53R158G may impede p65
activation through perturbation of the TRAIP-IĸB-NFĸB axis.
However, we noted in the qPCR and immunoblotting analyses
Fig. 4 Acetylation of mutp53 at the DBD is required for the induction of p53-dependent apoptosis. a, b Western blot measuring the changes in the
indicated protein after 48 h treatment with belinostat (PXD101; 0.1 μM) and cisplatin (CDDP; 10 μM) in Calu-1 isogenic cells generated through site-
directed mutagenesis (p53−/−, p53wt, p53R158G, p53R158G(DBD, K-A), p53R158G(CT, K-A), p53R158G(K20A)) (n= 3 independent experiments) (a). β-actin
shown as loading control. Densitometry of cleaved PARP (x-axis) and caspase 3 (y-axis) was quantified and normalized to β-actin, tabulated as ratio of
belinostat/cisplatin combination to cisplatin alone (b). Data are represented as mean of three independent experiments. c, d Cell cycle analysis (PI
staining) (c) and apoptotic profile (Annexin V staining) (d) were evaluated 48 hours post-treatment. Data are represented as mean IC50 ± SD (n= 4
independent experiments). Two tailed Student’s t-test; *P < 0.05. e–i RT-qPCR analyses of the changes in mRNA levels of MDM2 (e), CDKN1A (f), PUMA
(g), PMAIP1 (Noxa) (h), BAX (I) in p53−/−, p53wt, p53R158G cells 48 h post-treatment. Data are represented as mean ± SD (n= 3 independent
experiments). j Immunofluorescence staining was performed to determine the colocalization of acetyl-p53 (Lys382) (Alexa Fluor-488) and p-p53 (Ser15)
(Alexa Fluor-568) in p53wt and p53R158G cells. Eight independent fields were taken for each condition with a minimum of 50 nuclei per field. Representative
confocal images shown at ×40 magnification (n= 3 independent experiments). Merged images displayed with blue indicates DAPI, green indicates acetyl-
p53, red indicates p-p53, whereas yellow indicates colocalization of p- and acetyl-p53. Scale bar, 50 µm. k Tenovin-6 IC50 was quantified in Calu-1 isogenic
clones 72 h post-treatment. Data are represented as mean IC50 ± SD (n= 3 independent experiments). Two tailed Student’s t-test; *P < 0.05; **P < 0.01.
lWestern blot indicating changes in the indicated proteins in p53−/−, p53wt, p53R158G cells 48 h after vehicle or tenovin-6 treatment (3 or 10 μM). β-actin
shown as loading control (n= 3 independent experiments).
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that TRAIP was elevated to a certain extent in p53wt and p53−/−
(Fig. 5d, h). As TRAIP is involved in cellular response to
genotoxic lesions such as replication-associated DNA damage39,
we reasoned that TRAIP is induced as part of a p53-independent
physiological response to cisplatin-induced DNA cross-linking,
particularly in p53 null cells. To confirm this, we extended our
analyses on the remaining Calu-1 clones expressing p53R158G.
Belinostat/cisplatin co-treatment consistently elevate TRAIP and
suppress IĸB phosphorylation in these clones, whereas the same
treatment condition did not alter IĸB in p53wt and p53−/− cells
(Supplementary Fig. 10A, B).
Acetylated p53R158G suppresses NFĸB signaling through
TRAIP. To prove this hypothesis, we first determined the
changes in chromatin binding affinity of acetylated mutp53 in the
context of TRAIP transactivation. Using ChIP-quantitative PCR
(ChIP-qPCR), we validated the increased binding of p53R158G
after belinostat/cisplatin treatment to the promoter region of the
TRAIP gene (Supplementary Fig. 11A–C). In parallel experiments
involving p53wt and p53R158G(K20A) cells, there was no apparent
enrichment in term of wtp53 binding to TRAIP, and more
importantly, the ChIP-qPCR signal of mutp53 binding was
attenuated in the p53R158G(K20A) variant, which cannot be
acetylated (Supplementary Fig. 11B, C). Collectively, these find-
ings strengthened the concept that acetylation of p53R158G leads
to the transactivation of TRAIP (Fig. 5d).
We next sought to investigate the relevance of TRAIP
transactivation on NFĸB signaling in the context of differential
p53 alterations. NFĸB stimulation renders resistance to pro-
grammed cell death through nuclear translocation of its activated
heterodimeric complex, DNA interaction and induction of
50
40
50
40
40
15
p53 ChIP
PCNA
POLA2
RFC4
RAD51
TRAIP
USP1
POLE3
PSME3
CDK1
ANAPC7
PSMC4
CDC7
CYCS
CHEK1
TJP2
RBL1
MSH2
POLE
EXO1
ORC1
PMAIP1
CDKN1A
TNFRSF10B
RPS27L
MDM2
GADD45A
TDG
ATF3
Drug
p53
wt
p53
R1
58G
+
–
–
+
TRAIP
p5
3–
/–
p5
3
–
/–
p5
3–
/–
p5
3w
t
p5
3
wt
p5
3w
t
p5
3R
15
8G
p5
3
R1
58
G
p5
3R
15
8G p5
3R
15
8G
(DB
D, K
-A)
p5
3
R1
58
G(D
BD
, K-
A)
p5
3R
15
8G
(CT
, K-
A)
p5
3
R1
58
G(C
T, K
-A)
p5
3R
15
8G
(K2
0A)
p5
3
R1
58
G(K
20A
)
p5
3–
/–
p5
3w
t
p5
3R
15
8G
p5
3R
15
8G
(DB
D, K
-A)
p5
3R
15
8G
(CT
, K-
A)
p5
3R
15
8G
(K2
0A)
p5
3–
/–
p5
3w
t
p5
3R
15
8G
p5
3R
15
8G
(DB
D, K
-A)
p5
3R
15
8G
(CT
, K-
A)
p5
3R
15
8G
(K2
0A)
0
1
2
3
*
*
*
**TRAIP
0
5
10
15 DMSO
PXD101 0.1 μM 
+ CDDP 10 μM
R
el
at
iv
e 
Qu
an
tifi
ca
tio
n
R
el
at
iv
e 
Qu
an
tifi
ca
tio
n
R
el
at
iv
e 
Qu
an
tifi
ca
tio
n
*
P = 0.026
P = 0.031
*
–+ –+DMSO (0.1%) –+ –+
PXD +CDDP
–+ +
–+ –+ –+ –+ –+– +
p-IκB
Total IκB
β-actin
TRAIP
–
γH2AX
KMT2DKAT6A
0
1
2
3
R
el
at
iv
e 
Qu
an
tifi
ca
tio
n
0
1
2
3
a
b
d
e f g
c
h
fold change (log2)
R158G - R158G + WT + R158G +
WT - WT + WT - R158G -
DMSO COMB
Co
ve
ra
ge
 D
ep
th
 (r
ea
ds
/m
illio
n)
Coverage Depth (reads/million)
TRAIP
genes
4
3
2
1
0
–3.0 TSS
s3
s4
3.0 Kb
Color key
–3 –2 –1 0
Value
1 2 3
MEME (no SSC) 06.08.15 09:59
0
1
2
bi
ts
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
0.0 0.5 1.0 1.5 2.0
Fig. 5 Genome-wide binding and downstream transactivation of GOF p53R158G. a mutp53R158G-binding loci identified by p53 ChIP-seq analysis on Calu-1
cells treated with vehicle or belinostat/cisplatin combination for 24 h (n= 1). Meta-peak analysis showing distribution of p53R158G-binding sites across
3000 bp from the TSS of the nearest downstream gene (left, top). Density heatmap of the mutp53-binding sites (±3000 bp from TSS) examined by ChIP-
seq (Right). Canonical wild-type p53 consensus motif was identified by MEME/TomTom from the TSS-proximal ChIP-Seq peaks (bottom left).
b Comparisons of the transcriptomic levels of differentially-expressed genes (AmpliSeq analysis) bound by p53 (ChIP-seq analysis) under vehicle (−) or
drug-treatment (+) conditions. Colors from green to red indicate increasing RNA level (fold change as indicated) in each pair. Individual fold change values
were tabulated in Supplementary Table 4. c Integrative Genomics Viewer display of mutp53 occupancy over promoter region of TRAIP gene in vehicle- or
drug-treated cells (p53wt, p53R158G). d RT-qPCR quantification of TRAIP gene in Calu-1 (p53−/−, p53wt, p53R158G) cells 48 h after vehicle or drug
treatment. e–g RT-qPCR analyses of the basal mRNA levels of TRAIP (e), KAT6A (f) and KMT2D (g) in various p53 clones, compared to p53−/−. Data are
represented as average relative quantification ± SD (n= 3 independent experiments). Two tailed Student’s t-test; *P < 0.05; **P < 0.01. h Immunoblotting
was performed to evaluate the effects of belinostat/cisplatin on the indicated targets in various p53 clones. β-actin shown as loading control (n= 3
independent experiments).
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-15608-y
8 NATURE COMMUNICATIONS |         (2020) 11:2086 | https://doi.org/10.1038/s41467-020-15608-y | www.nature.com/naturecommunications
survival signals, which is regulated by an auto feedback loop
involving its negative regulator IĸB47. Activation of NFĸB is
determined either by the canonical NFĸB1/RelA complex or the
non-canonical NFĸB2/RelB complex. While wtp53 and NFĸB are
often coordinated in an opposing manner due to their contrasting
cellular functions48,49, mutp53 proteins have been shown to
promote NFĸB activation11. In the context of LUSC, we first
showed using DNA-binding ELISAs that cisplatin treatment
increased p65 (RelA, NFĸB p65 subunit) transactivation in p53wt
cells (Fig. 6a). In contrast, a reciprocal downregulation was
observed in p53R158G cells, with a further reduction observed
when combined with belinostat; whereas NFĸB was unaffected in
p53 deficient cells (Fig. 6a). To rule out the possible alternative
involvement of non-canonical NFĸB signaling, we investigated
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the transactivation of p52 (NFĸB2 subunit) and showed that
DNA-binding was marginally affected in all cell types (Fig. 6b)50.
Cytoplasm to nuclear shuttling of p65 is critical for the initiation
of the NFĸB pathway51. In p53R158G cells, drug treatment
reduced nuclear accumulation of p65; conversely, pronounced
p65 nuclear translocation was observed in wild-type cells, in
concordance with the increase in DNA-binding assays (Fig. 6c–f).
The wtp53-p65 relationship was illustrated experimentally in
colon cancer cells HCT116 p53 wild-type/null pairs52, where drug
combination induced p65 nuclear translocation in wild-type
(HCT116+/+) but not in null (HCT116−/−) cells (Supplementary
Fig. 12A–D). In addition, we observed that basal nuclear NFĸB is
kept at levels lower in p53wt than in p53R158G or p53 null cells
(Fig. 6c–f, Supplementary Fig. 12A, B), likely through higher
TRAIP expression in wtp53 cells (Fig. 5e). Together, our findings
support the contention that increased transcription of TRAIP by
acetylated p53R158G leads to inhibition of NFĸB through blocking
IĸB phosphorylation and nuclear import of p65.
To elucidate the mechanisms relating TRAIP to NFĸB
inhibition, we overexpressed TRAIP in both p53−/− and p53wt
cells. Surprisingly, cisplatin alone or in combination down-
regulated exogenous TRAIP in p53−/− cells without affecting the
downstream targets (Fig. 6g, left). In contrast, ectopic TRAIP
expression was sustained in p53wt cells, leading to the down-
regulation of TRAF2, c-IAP1, and c-IAP2, pro-survival compo-
nents of the TNF receptor family53, potentially through the
ubiquitin-proteasomal degradation pathway (Fig. 6g, right).
These data are consistent with previous work demonstrating that
TRAF2 and c-IAP are downstream effectors of TRAIP42,45. As
previously described54, ablation of TRAF2 reduced phosphoryla-
tion and degradation of IĸB (Fig. 6g, right), therefore facilitating
IĸB-mediated impediment of NFĸB transactivation (Fig. 6h). This
negative NFĸB regulation by exogenous TRAIP sensitized p53-
expressing cells to drug-induced apoptosis, as indicated by
increased Annexin V positive population and PARP cleavage
(Fig. 6i–j). Importantly, exogenous TRAIP recapitulated p53R158G
response to drug treatment in p53wt cells. Consistently, acetyla-
tion of p53R158G is associated with p21 upregulation, p-IĸB
suppression and elevated TRAIP transcript in H2170 cells
(Supplementary Fig. 13A–C). Of note, these modulations were
consistent in other cell types expressing Arg158 mutp53 (H441,
H661), but were not found in other GOF mutp53 cells (H1417,
H1975, HCC70, MDA-MD-468, and SK-BR-3 cells) (Supple-
mentary Fig. 13A, B), thereby highlighting the mechanistic dis-
tinctiveness of the Arg158 mutp53. Effective silencing of TRAIP
markedly rescued cellular apoptosis in H2170 cells, as demon-
strated by the reduced PARP and caspase 3 cleavage, by
sustaining p-IĸB without affecting p53 acetylation (Supplemen-
tary Fig. 13D). It is interesting to note that TRAIP expression was
consistently detected in the DMSO-treated cells upon siRNA
interference, and we reasoned that the presence of a compensa-
tory mechanism could potentially stabilize TRAIP and counter-
balance the knockdown effect. We postulate that this mechanism
could be impaired under cellular stress, thus allowing knockdown
of TRAIP to be possible upon drug treatment. However, the
detailed mechanism remains elusive at this moment.
To further investigate the mechanisms of the TRAIP/TRAF2/
NFĸB axis, dominant negative IĸBα mutants (IĸBα-ΔN, IĸBα-
S32A) were introduced to shut off NFĸB activity. As expected,
dephosphorylation of IĸB in wtp53 cells reduced p-p65, p-
TRAF2, and c-IAP2 upon drug treatment, recapitulating the
effects of TRAIP overexpression (Supplementary Fig. 16A).
Surprisingly, transfection of IĸBα mutants has little effect in
p53−/− cells, and conversely, p65 was highly phosphorylated.
Functionally, NFĸB inhibition also induced pronounced apopto-
sis in wtp53 and mutp53 cells, but to a lesser extent in null cells
(Supplementary Fig. 16B). Collectively, these data strongly
suggest a direct role of TRAIP, expressed upon acetylation of
mutp53R158G, in facilitating apoptosis through disruption of
NFĸB pathway signaling.
Potent p53 acetylators reduce mutp53 tumor growth. Further
analyses of compounds found active against p53R158G cells
revealed that eight out of the 10 compounds induced p53R158G
acetylation (Supplementary Fig. 15A), which was correlated to
increased p21, elevated CDKN1A and TRAIP transcripts, sup-
pression of TRAF2 and p-IĸB, as well as augmented PARP
cleavage (Supplementary Fig. 15A, D, E), thus supporting our
earlier observations. On the contrary, exposure to these acet-
ylators induced stabilization of wtp53 and upregulated p21,
increased MDM2 and CDKN1A transcripts, but had minimal
impact on p-IĸB and TRAIP mRNA (Supplementary Fig. 15B–E),
thereby highlighting the specificity of these single agents in tar-
geting mutp53R158G cells.
When applied in vivo, single agent cisplatin was effective in
reducing tumor growth of p53R158G xenograft as compared to
vehicle, with no efficacy observed in p53−/− and p53wt tumors
(Supplementary Fig. 16A–C). Of note, efficacy of cisplatin in the
p53R158G(K20A) tumors with defective acetylating mechanism was
evidently reduced (Supplementary Fig. 16A–C). Mechanistically,
acetylation of mutp53R158G was accompanied by elevated TRAIP
(Supplementary Fig. 16E), p65 inhibition (Supplementary Fig. 16F)
and reduced Ki67 staining, a marker for cellular proliferation
(Supplementary Fig. 16G); in contrast with increased p65 nuclear
accumulation and lack of efficacy in the wtp53 tumors. Scoring of
TRAIP transcripts demonstrated a reciprocal inverse correlation
with NFĸB activity, for instance, a high basal score was associated
Fig. 6 Drug-induced TRAIP expression negatively regulates NFĸB signaling in p53R158G cells. a, b Quantification of active nuclear NFĸB1 (p65) (a) and
NFĸB2 (p52) (b) in Calu-1 (p53−/−, p53wt, p53R158G) cells 48 h after vehicle or drug treatment. Data are presented as mean ± SD (n= 3 independent
experiments). c, d Distribution of p65 (in cytoplasm or nucleus) was determined by Western blot (c) after nuclear-cytosolic fractionation. TATA-box
binding protein (TBP) (nuclear) and α-tubulin (cytoplasmic) were used as loading controls. Nuclear p65 expression was quantified with
densitometry after normalizing to TBP (d). Data are presented as mean ± SD (n= 3 independent experiments). Two tailed Student’s t-test; **P < 0.01.
e, f Immunofluorescence staining was performed to determine the localization of p65 (Alexa Fluor-488) in p53wt and p53R158G cells 48 h post-treatment.
At least five independent fields were taken for each condition with a minimum of 30 nuclei per group (n= 3 independent experiments). Representative
confocal images shown at 63× magnification (e). Scale bar, 10 µm. Merged images displayed with blue indicates DAPI, green indicates p65. Integrated
density quantifying nuclear NFĸB (p65) in p53wt and p53R158G cells (f). Data are presented as mean ± SD (n= 3 independent experiments). Two tailed
Student’s t-test; *P < 0.05. g Western blot showing effects of TRAIP overexpression on the indicated proteins in Calu-1 isogenic cells (p53−/−, p53wt,
p53R158G) 48 h after vehicle or drug treatment. β-actin shown as loading control (n= 3 independent experiments). h Quantification of active nuclear NFĸB1
(p65) in Calu-1 (p53−/−, p53wt, p53R158G) cells after TRAIP overexpression with the indicated drug treatment. Data are presented as mean ± SD (n= 3
independent experiments). i, j Annexin V staining (i) and Western blotting (j) in TRAIP overexpressed cells 48 h post-treatment. Data are presented as
mean ± SD (n= 3 independent experiment). Two tailed Student’s t-test; *P < 0.05, **P < 0.01.
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with low p65 accumulation in p53wt tumors (Supplementary
Fig. 16H). Further analyses of vehicle- and cisplatin-treated
xenograft for drug-activity showed elevated TRAIP mRNA copies
in p53R158G tumors, but decrease in wild-type tumors, validating
the in vitro data (Supplementary Fig. 16H). We expanded our
in vivo studies to screen for efficacy of other potent acetylating
agents, as the clinical application of HDACi has been challenging
in solid cancers, possibly due to their poor therapeutic index55.
Whereas volasertib demonstrated high toxicity in mice (died
within days of administration), tolerable doses of JQ1 and
topotecan were effective in suppressing growth of p53R158G
tumors compared to the p53wt and p53−/− counterparts
(Supplementary Fig. 16I-K), providing direction for future
development of p53-acetylating agents in p53R158G-positive
tumors.
Patient-derived xenograft (PDX) tumors of gastric cancer (GC;
p53R158C) and hepatocellular carcinoma (HCC; p53R158H)
harboring Arg158 mutp53 were selected for evaluation with
p53-acetylators: cisplatin, JQ1 and topotecan. All three com-
pounds significantly reduced tumor growth in both PDX models
(Fig. 7a, b, d, e) at tolerable doses (Fig. 7c, f). Tumor specimens
from GC-PDX showed that cisplatin and topotecan significantly
induced p53 acetylation and phosphorylation, with TRAIP
upregulation as well as PARP cleavage observed in most of the
treated tumors (Fig. 7g). Moreover, we demonstrated using RNA
in situ hybridization the transcriptional induction of TRAIP
mRNA in the drug-treated tumors (Fig. 7h, i), which was
concordant with the protein expression in the matched tumor
samples (Fig. 7g). These findings suggest that, while the Arg158
p53 mutation is more prevalent in lung carcinomas, the
mechanism conferring tumor cytotoxicity could be applied across
cancer types harboring the same alteration. We further explored
the potential of combining a DNA-damaging agent (cisplatin)
with an effective p53-acetylating agent (topotecan) in both PDX
models. Compared with single agents, combination of cisplatin/
topotecan rapidly and profoundly suppressed tumor growth with
no significant weight loss observed in all animals (Fig. 7j), with
tumor regression observed in multiple cases (Fig. 7k).
Discussion
Missense mutations in the DNA-binding domain constitute more
than 70% of tumor-associated p53 mutations. These mutations
alter DNA-binding capability of mutp53, concomitantly leading
to a variable loss of p53 tumor suppressive functions, while
mediating oncogenic GOF through transcriptional aberrations
involving chromatin remodeling and interaction with transcrip-
tion cofactors such as SREBP, ETS2, or NRF26,22,37,56. Ther-
apeutic interventions that have been proposed to target mutp53
cells include attempts to exploit the loss of checkpoint
function27,28, inhibit the GOF pathways6,29, and direct destabi-
lization of the mutated protein;9,10 but these have yet to gain
clinical traction. Whether these strategies can be applied globally
to all mutp53 remains debatable, as only the six most common
“hotspot” mutants have been studied in depth. We studied a GOF
Arg158 mutp53 in the DBD found to be relatively frequent in lung
carcinomas, and elucidated a unique pathway of mutp53 that can
be exploited therapeutically.
The complex crosstalk between p53 and NFĸB has been
described previously, with the suppression of p65 in wild-type
cells a result of competitive interaction with p300 or glucocorti-
coid receptor;48,49 conversely mutp53 prolongs and enhances
NFĸB activation11,12,57,58. We propose here a mechanism for this
divergent effect through acetylation of Arg158 mutp53, which
alters its DNA-binding spectrum and upregulates TRAIP as key
target gene, leading to NFĸB suppression through TRAF2
degradation and culminating in cell death (Fig. 8). This p53 iso-
form appears to carry distinctive GOF mechanisms that does not
involve the chromatin regulatory genes as observed in other
DBD hotspot mutants; other hotspot p53 mutants, such as
R175H and R273H, did not upregulate TRAIP in response to
belinostat and cisplatin treatment. Given that a point mutation is
sufficient to affect p53 transactivation59, and that protein mis-
folding regulated by zinc-binding could affect p53 transcriptional
functions60, it is possible that Arg158 mutp53 modulates site-
specific DNA binding through aberrant Zinc2+ interaction
which should be explored further. One possible caveat of the
study is the lack of a universal cellular system to distinguish
the functions of the various GOF mutp53. The inability to
establish a robust CRISPR-Cas9 model has prevented us from
studying this.
Our expression analysis and ChIP-Seq findings concordantly
demonstrated the retention of transcriptional activity of
mutp53R158G, which has been described in other DBD variants.
Exposure to cellular stress, such as cisplatin, could trigger a partial
wild-type activity in mutp53R158G that induces p53-dependent
pro-apoptotic signals, which is not seen in p53 null cells. How-
ever, the DNA-binding activity of mutp53R158G is distinct from
p53wt, manifesting in GOF activity. Paradoxically, this DNA-
binding ability is prerequisite for the induction of apoptosis as
initiated through mutp53R158G acetylation, a key post-
translational event closely associated with its transcriptional
activity and stability61,62. Loss of acetylation, particularly at the
DBD, significantly impacted cell cytotoxicity, indicating that this
post-translational event is indispensable for mutp53 activation.
We studied this using in silico modeling of the expected mole-
cular disruptions effected by the acetylation of DBD, and
our simulation suggested strongly that the distorted mutp53
conformation could be restored through acetylation within the
DBD, which appears to act as a stabilizing factor to facilitate the
formation of a functional and stable mutp53 dimers with strong
DNA-binding affinity. These further refined the commonly held
credence that targeting acetylation and eventual depletion of
mutp53 is a plausible anti-tumor approach63. Such findings are
made therapeutically relevant by positive screen hits for com-
pounds with pharmacological activity of p53R158G acetylation.
The selective cytotoxicity of these compounds in Arg158
mutp53 tumors, compared to wild-type and null tumors, is
promising as a companion biomarker for selecting patients with
greater potential to respond to the p53-acetylating agents. From
the therapeutic standpoint, dosages of acetylating agents used in
the xenograft experiments were well-tolerated, further heighten-
ing the possibility of clinical translation. For instance, the bro-
modomain (BRD) inhibitor JQ1 is currently in clinical
development to target a rare genomic BRD-NUT fusion event in
NUT midline carcinoma64, and our data extends potential eva-
luation in Arg158 mutp53 tumors. Curated data from public
databases (IARC TP53, COSMICs, ICGC, and cBioportal) reveal
the presence of Arg158 mutp53 in multiple carcinomas; and the
effectiveness of mutp53 acetylators in the PDX models of gastric
and liver cancers further extends the applicability of these find-
ings to other cancer types.
In conclusion, we provide evidence of a unique mechanism of
p53 activation that is specific to Arg158 mutations, exposing a
previously unrecognized therapeutic vulnerability and facilitating
a biomarker-implemented approach directed against this GOF
mutant. This is unsurprising, as it has been recently recognized
that different p53 mutations are attributable to distinctive phe-
notypes and cellular effects65,66, and our work adds to this. If
validated in the clinic, this represents an advance in therapeutic
treatment of tumors with mutated p53, particularly that of LUSC,
in which Arg158 mutant is found to be prevalent.
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Methods
Genomic analyses of human cancers. The pan-cancer mutation annotation file
were downloaded from GDAC (version 2016_01_2825). Mutations found on TP53
genes and the corresponding protein change were extracted for analysis.
Cell culture. Cancer cell-lines (Calu-1, ChaGo-k-1, HCC70, H441, H520, H596,
H661, H747, H1417, H2170, MDA-MB-468, SK-BR-3, SK-MES-1) and lung
fibroblast cells (MRC-5) were obtained directly from the American Type Culture
Collection (ATCC), while others (A549, BT-549, H1975, MIA-Paca-2, PANC-1)
were provided by Ashok Venkitaraman (MRC Cancer Unit, Cambridge, UK).
Cultures were maintained in a humidified 37 °C incubator, in culture medium
(according to ATCC’s recommendation) supplemented with 10% fetal bovine
serum, 2 mM L-glutamine, 100 μg mL−1 streptomycin and 100 U mL−1 penicillin.
Paired HCT116 p53−/− and p53+/+ cell-lines were obtained from Bert Vogelstein
(The John Hopkins Medical School, Baltimore, MD) as a gift. Isogenic Calu-1 cells
stably expressing pcDNA3.1 vector, pcDNA3.1-p53wt, pcDNA3.1-p53R158G,
pcDNA3.1-p53R158G(DBD, K-A), pcDNA3.1-p53R158G(CT, K-A), pcDNA3.1-
p53R158G(K20A) plasmids, respectively, were generated by transfection and
single-cell selection.
Transwell invasion assay. Matrigel invasion assay was carried out with Corning®
BioCoat™ Matrigel Invasion Chambers (#354480). In brief, 25,000 (for Calu-1) or
50,000 (H2170) cells were plated in the transwell chamber with serum-free med-
ium. For gene silencing experiments, cells were incubated with siRNA overnight
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prior to plating. Tumor cells were allowed to invade for 24–36 hours before the
transwell inserts were fixed with 4% paraformaldehyde, stained with gentian violet
and imaged for analysis. Number of invaded cells was quantified with ImageJ
Software (NIH), and expressed as mean ± SD.
Anchorage-independent soft agar assay. The colony forming assay comprises
three layers of soft agar/medium matrix in 24-well plate: a bottom layer of 0.6%
agar matrix; a middle layer containing 0.36% agar matrix with the indicated cells
(10,000 cells/well); and a top layer comprising complete medium. Culture medium
were changed weekly. For gene silencing experiments, cells were incubated with
siRNA overnight prior to culturing in soft agar. After 4 weeks of culture, colonies
were stained with MTT stain (Promega, #G4000) for 2 h and imaged. Colonies
were counted with ImageJ Software, and expressed as mean ± SD.
PCR and sequencing. Total RNA was isolated from cells using RNeasy kit
(Qiagen, #74106) and reverse-transcribed to cDNA using iScript RT Supermix
Fig. 7 Cisplatin, JQ1 and topotecan reduce tumor growth in PDX models harboring Arg158 p53 mutations. a–f Efficacy of cisplatin, JQ1 and topotecan
were investigated in PDX model of gastric cancer (GC) and hepatocellular (HCC) cancer. Growth curve analysis of GC-PDX (a) and HCC-PDX (d) treated
with vehicle, cisplatin (CDDP; 4 mg kg−1), JQ1 (30mg kg−1), or topotecan (1 mg kg−1). Tumor sizes are presented as mean ± SEM. Two-way ANOVA with
Bonferroni correction; *P < 0.05; **P < 0.01; ***P < 0.001. Waterfall plots showing change in tumor volume (relative to initial tumor volume at treatment-
start day) for each individual GC-PDX (b) and HCC-PDX (e) tumor in respective treatment group. Bodyweight of mice with GC-PDX (c) and HCC-PDX (f)
at assay endpoint was tabulated as mean ± SD. g Western blots demonstrating changes of the indicated proteins in tumors of respective treatment (n= 3
independent tumors). β-actin shown as loading control. Densitometric quantification of TRAIP expression was tabulated on the right. Relative fold change is
normalized to β-actin, relative to vehicle control tumors. Data presented as mean ± SD. Two tailed Student’s t-test; *P < 0.05, **P < 0.01. h–i RNA in situ
hybridization (RNAscope) showing TRAIP expression in respective tumors. Representative images showing TRAIP mRNA signal are shown at ×20
magnification (h). Scale bar, 50 µm. Semi-quantitative scoring (0–4) of TRAIP mRNA signal (dots/cell) in p53wt and p53R158G, respectively, was tabulated
(i). Data are represented as scattered dot plot ± SD (n= 5 independent tumors). Two tailed Student’s t-test, *P < 0.05. j–k Efficacy of cisplatin and
topotecan combination were investigated in PDX models of gastric cancer and hepatocellular cancer. j Growth curve analyses of GC-PDX and HCC-PDX
treated with vehicle, cisplatin (CDDP; 4mg kg−1), topotecan (1 mg kg−1) or CDDP/topotecan combination. Tumor sizes are presented as mean ± SEM.
Two-way ANOVA with Bonferroni correction; *P < 0.05; **P < 0.01; ***P < 0.001. k Change in tumor volume (relative to initial tumor volume at treatment-
start day) for each individual tumor in respective treatment group were calculated and tabulated into four groups (>500%; >200% <500%; >100%
<200%; <100%). Tumor volume below 100% indicates tumor regression.
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Fig. 8 Proposed mechanism of Arg158 mutp53 in response to treatment with acetylating agents. Tumor cells harboring mutp53 expressed inherently
high level of NFĸB activity to confer cellular survival. We showed that in mutp53R158G cells, NFĸB/p65 signaling could be suppressed through negative
regulation of the TRAF2/c-IAP/IĸB-axis via the upregulation of TRAIP, which is induced transcriptionally by monotherapy or combination treatment of
compounds shown to induce mutp53 acetylation.
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(Bio-Rad, #1708841). Sanger sequencing were carried out on amplified DNA to
sequence region of interest according to standard protocol. Real-time qPCR was
performed in triplicates using standard procedures on a 7500HT Fast-Real-Time
PCR platform (ABI), using probe-based assays. Gene expressions were normalized
to the housekeeping gene GAPDH. ChIP was performed using Active Motif ChIP-
IT ChIP-seq kit according to manufacturer’s protocol with slight modifications. In
brief, cells were crosslinked with 1% formaldehyde, glycine quenched, lysed with
cell lysis buffer (Sigma, #2978) supplemented with 1 mM PMSF, and subjected to
pulse sonication (20 s with 30 s internal, five cycles). The supernatant was then
immunoprecipitated with the p53 and rabbit IgG antibodies (Cell Signaling, #9282
and #2729) at 4 °C overnight and incubated with Magna ChIP Protein G magnetic
beads (Millipore, #16-662). The beads were washed before DNA was reverse-
crosslinked and purified. For ChIP-Seq, sequencing libraries were prepared using
TruSeq DNA LT Sample Prep kits, and pair-end sequencing was performed on
Illumina Hi-Seq platform. ChIP-qPCR validation was performed in triplicates
using standard procedures on a 7500HT Fast-Real-Time PCR platform (ABI),
using primer-based assays. For Ion AmpliSeq Transcriptome Human Gene
Expression (Thermo Fisher), 10 ng RNA was used for barcoded cDNA library
preparation using PCR-based targeted-amplicon amplification according to man-
ufacturer’s protocol. Pooled libraries were amplified with emulsion PCR on Ion
Torrent OneTouch2 instruments (OT2) and sequenced on Ion Torrent Proton
sequencing system. Both Hi-Seq and AmpliSeq were performed at AITbiotech
(Singapore), Sanger sequencing at Axil Scientific (Singapore). All primer sequences
used for RT-qPCR and ChIP-qPCR in this study are tabulated in Supplementary
Table 5.
Chemical screening, compounds, cell viability assay. Selleckchem Anti-cancer
compound Library (414 compounds, #L3000), Enzo Epigenetic Library (43 mod-
ulators, #BML-2836) and Selleckchem Epigenetic Library (151 modulators,
#L1900) were used for high-throughput chemical screening. Bleomycin (S1214),
AZD7762 (S1532), cladribine (S1199), topotecan (S1231), nocodazole (S2775),
volasertib (S2235), BI-2536 (S1109), 17-AAG (S1141), belinostat (PXD101, S1085),
bosutinib (S1014), MK-5108 (S2770), JQ1 (S7110), CX-6258 (S7041), alisertib
(S1133), JNJ-26481585 (S1096), and M344 (S2779) were purchased from Sell-
eckchem; oxamflatin was purchased from Sigma Aldrich (O3139). All compounds
were dissolved in Dimethyl sulfoxide (DMSO, Sigma Aldrich, #D8418). Cisplatin
was obtained from Hospira Pharmaceuticals. Approximately 3000/1000 cells were
seeded per well into a 96/384-well plate 24 h prior to drug treatment. For high-
throughput studies, cultures were dispensed (50 µL) into 384-well plates using a
MultiFlo dispenser, while drugs were 100-fold diluted in DMSO and kept at 1% (v/
v) across all drug concentrations and control. The cell viability was assayed at 72 h
post-treatment using either CellTiter-Glo luminescent or CellTiter-96 Aqueous
One cell viability reagent (Promega, #G7572 and G3582). The luminescence signals
were detected using TECAN Infinite M1000 pro multi-mode plate reader using an
integration time of 1000/250 ms. Absorbance was recorded at 490 nm. The relative
luminescence/absorbance units from treated wells were normalized against DMSO
control wells and expressed as percentage cell viability. IC50 values were calculated
using GraphPad Prism software.
Drug screening bioinformatics, Bliss Independent index. Drug response of the
Calu-1 cell-lines were quantified using the Inhibition score (I-score). For each
compound c, the I-score was determined as follows:
I  score cð Þ ¼ 1 Luminescence signal cð Þ
Median of Luminescence signal DMSOð Þ
 
´ 100
where the denominator is the median of the luminescence emitted in presence of
Dimethy sulfoxide (DMSO). The inhibition heatmap of selected drugs (filtered at
I-score >50 in at least one of the cell-lines) between the Calu-1 wild-type, mutant
and null cell-lines were hierarchically clustered using complete linkage clustering
and Euclidean distance measure. Combination Index (CI) was calculated based on
the Bliss Independence model, by considering all dose combinations tested
(observed combination response against the predicted combination response). By
assuming that there is not drug-drug interaction, the combination effect is declared
synergistic if the observed response is greater than the predicted response (Bliss < 0).
Western blotting, cellular fractionation, and antibodies. The sodium dodecyl
sulfate–PAGE (SDS-PAGE) was performed as described previously67. Whole-cell
lysates were extracted with cell lysis buffer (Sigma, #2978) supplemented with
protease and phosphatase inhibitors (ThermoFisher, #78440). Protein concentra-
tion was determined by BCA protein assay (Life Technologies, #23227), and equal
amount of proteins were separated using SDS-PAGE. Cytosolic and nuclear frac-
tionations were performed according to manufacturer’s protocol (Active Motif,
#40010). The ratio of cytoplasmic to nuclear proteins was 3:1 for Western blotting.
Antibodies used for immunoblotting include: PARP (#9542), cleaved PARP
(#5625), caspase 3 (#9662), caspase 7 (#9492), acetyl-H3K23 (#9674), acetyl-
H3K9K14 (#9677), total H3 (#9715), phospho-p53 Ser15 (#9286), acetyl-p53 Lys
382 (#2525), acetyl-p53 Lys379 (#2570), total p53 (#9282), p21 (#2947), γH2AX
(#9718), phopho-IĸB Ser32 (#2859), total IĸB (#9247), total p65 (#8242), phoshph-
TRAF2 Ser11 (#13908), total TRAF2 (#4724), c-IAP1 (#7065), c-IAP2 (#3130),
α-tubulin (#2125), and horseradish peroxidase (HRP)-conjugated β-actin (#5125)
antibodies as well as secondary anti-mouse (#7076) and –rabbit (#7074) HRP-
conjugated secondary antibodies were obtained from Cell Signaling Technologies;
acetyl-H4 (#06-866) antibody was from Merck Millipore; TRAIP (#ab80170),
TATA-box binding protein (#ab818) were from Abcam; DDK (#TA180144)
antibody was from Origene. All antibodies were used at 1:2000 dilution.
Caspase activity, apoptosis and cell cycle assays. Caspase 3/7 enzyme activities
were measured by using Caspase-Glo 3/7 Assay Systems (Promega, #G8090)
according to manufacturer’s protocol. Cells were incubated with indicated com-
pounds for 24 h, and the luciferase activities were measured after substrate incu-
bation with a TECAN Infinite plate reader. Apoptosis assay was carried out using
annexin V-APC (Thermo Fisher, #A35110) and propidium iodide (PI, BD Bios-
ciences, #556463) according to manufacturer’s protocol. In brief, harvested cells
(0.2 × 106) were washed with PBS followed by annexin V buffer (Thermo Fisher,
#V13246), and stained with Annexin V/PI mixture for 15 min at 25 °C. Cell cycle
fractions were determined through PI nuclear staining. In brief, harvested cells
(0.2 × 106) were fixed with 70% cold ethanol, and stained with PI staining buffer
(0.03 mgml−1 PI, 0.1 mg ml−1 RNAse A, 0.1% Triton-X in PBS) for 30 min at
25 °C. The staining profile was acquired (≥10,000 cell events) using LSR II Flow
Cytometer (BD Biosciences). The acquisition was analyzed using the FlowJo
8.1.1 software (Tree Star).
Plasmids and transfection. For stable overexpression in Calu-1 cells, wtp53
(pcDNA3.1-p53wt) and mutp53 (pcDNA3.1-p53R158G) sequences were cloned
from MRC-5 and H2170 cell-lines, respectively, while site-directed mutagenesis
was performed for substitution of Lysine residues to Alanine in the indicated
plasmids [pcDNA3.1-p53R158G(DBD, K-A), pcDNA3.1-p53R158G(CT, K-A),
pcDNA3.1-p53R158G(K20A)] using QuikChange Lightning Kit (Agilent,
#210519). For stable knockdown of p53, H2170 cells were transfected with
pLKO.1-puro Non-Target shRNA Control (shNT, Sigma Aldrich, SHC016),
pLKO.1-puro Luciferase shRNA Control (shLuc, Sigma Aldrich, #SHC007), or
shRNAs targeting TP53 (gifts from Cheok CF, IMCB, A*Star, Singapore). For
transient overexpression, pCMV6-Entry vector and pCMV6-TRAIP-DDK was
obtained from Origene, while pCMV-IĸB(ΔN) and pCMV-IĸB(S32A) are gifts
from Pieter Johan Adam Eichhorn (Cancer Science Institute of Singapore). Plasmid
transfections were carried out with FuGENE HD (Promega, #E2311). For transient
gene knockdown, TP53 siRNA (sequence: 5’-ACUCCACACGCAAAUUUCCTT-
3’), TRAIP siRNA (sequence: 5’-UUACACCUCAGGCUGGUCCCG-3’) and All-
Star negative control siRNA were obtained from Qiagen. siRNA transfection was
conducted with JetPRIME reagent (Polyplus Transfection).
Reporter-luciferase assay. The transcriptional activity of p53 was assessed by
reporter-luciferase assay. Cells were co-transfected with a combination of Cignal
reporter plasmids (Qiagen, # CCS-004L), including a mixture of inducible p53-
responsive firefly luciferase construct or non-inducible firefly luciferase construct,
with constitutively expressing Renilla luciferase construct. The cells were then drug
treated for the indicated durations, and luciferase assay was performed with Dual
Luciferase Reporter Assay System (Promega, #E1910) according to manufacturer’s
instructions and detected by Lumat LB 9507 (Berthold Technologies). The ratio
between Renilla luciferase across samples was used to normalize the transfection
efficiency.
In vitro translation (IVT), acetylation, and EMSA. IVT was performed according
to manufacturer’s protocol (Thermo Scientific, #88881). Briefly, 1 µg each of
pcDNA3.1-p53wt and pcDNA3.1-p53R158G plasmids were incubated with the
Hela extract and reaction mix for 6 h at 30 °C. The in vitro protein acetylation
(IVA) assay was performed, with a standard reaction included half of the sample
from the IVT assay, 0.5 µg of histone acetyltransferase domain of p300/CBP pro-
tein (Upstate, #14-418), 4 µg of Acetyl-CoA (Sigma, #A2056) and diluted in assay
buffer (final concentration of 50 mM Tris–HCl, pH 8.0, 10% glycerol, 0.1 mM
EDTA, 1 mM dithiothreitol). The reaction mix was incubated for 6 h at 30 °C in a
shaking incubator. The expression and acetylation of the respective p53 proteins
were validated with immunoblotting.
Electrophoretic mobility shift assay (EMSA) was conducted according to
manufacturer’s protocol (Thermo Scientific, E33075). 31-mer oligo containing p53
response element of CDKN1A gene (5’-CAGCATGCTCCAGGTAGAAGGAAA
CAGGCCC-3’) was ordered from IDT. Briefly, 50 ng of the synthesized oligos was
incubated with 2 μl of the reaction containing the respective p53 isoforms, and
incubated for 2 h at 30 °C. The samples were then separated by PAGE using 6%
non-denaturing gel. DNA and protein were stained simultaneously with SYBR®
Green nucleic acid gel stain and SYPRO® Ruby protein gel stain, respectively. The
images were then visualized and captured using UV transilluminator.
Molecular dynamics simulations of p53. The dimeric structure of the p53 DNA-
Binding Domain (DBD) complexed to a small fragment of DNA (PDB ID: 2AHI)
was taken from the RCSB Protein Data Bank. Molecular dynamics (MD) simula-
tions of the p53-DBDWT, p53-DBDR158G, and acetylated Lysine p53-DBDR158G
were carried out with the pemed.CUDA module of the program Amber16 with the
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Amber 14SB force field (ff14SB). Force field parameters for acetylated Lysine were
taken as described previously68. The Xleap module was used to prepare the system
for the MD simulations. All the simulation systems were neutralized with appro-
priate numbers of counterions. Each neutralized system was solvated in an octa-
hedral box with TIP3P water molecules, leaving at least 10 Å between the solute
atoms and the borders of the box. All MD simulations were carried out in explicit
solvent at 300 K. During the simulations, the long-range electrostatic interactions
were treated with the particle mesh Ewald method using a real space cutoff distance
of 9 Å. The Settle algorithm was used to constrain bond vibrations involving
hydrogen atoms, which allowed a time step of 2 fs during the simulations. Solvent
molecules and counterions were initially relaxed using energy minimization with
restraints on the protein and inhibitor atoms. This was followed by unrestrained
energy minimization to remove any steric clashes. Subsequently the system was
gradually heated from 0 to 300 K using MD simulations with positional restraints
(force constant: 50 kcal mol−1 Å−2) on the protein over a period of 0.25 ns
allowing water molecules and ions to move freely. During an additional 0.25 ns, the
positional restraints were gradually reduced followed by a 2 ns unrestrained MD
simulation to equilibrate all the atoms. Production simulations were carried out for
250 ns each in triplicates. Enhanced conformational sampling was carried out by
subjecting the systems to accelerated MD (aMD) implemented in AMBER 16,
using the “dual-boost” version. Conventional MD simulations carried out earlier
were used to derive the aMD parameters (EthreshP, alphaP, EthreshD, alphaD).
aMD simulations were carried out for 250 ns each. Simulation trajectories were
visualized using VMD and figures were generated using Pymol.
Chromatin immunoprecipitation (ChIP)-seq, AmpliSeq analyses. At least 16
million 51-bp long reads were mapped to hg19 using bowtie v2.1.0 with parameters
-N 1 –sensitive -p 2 –no-unal. Peaks were identified by MACS 2.0.9 using a
maximum of 2 reads per unique position and otherwise default parameters. Only
highly enriched (enrichment over background ≥5-fold, pileup ≥25) and highly
significant (q-value < 0.01) peaks were shortlisted from the analysis. de novo motif
search was conducted by MEME-ChIP54 using the TSS proximal peaks center
extended by 75 bp in both directions to determine the distribution of wtp53 and
mutp53-binding sites post-treatment with reference to hg19 annotations. MEME
was programmed to search for the top 10 motifs with significant matches between
query and target database using HOMER (Hypergeometric Optimization of Motif
EnRichment) 55 v4.5. The heatmaps of p53 enrichments (wtp53 and mutp53R158G)
across 3 kb region from peak centre were plotted using ngsplot, v2.61. For
AmpliSeq, fastq files were analyzed with the ampliSeqRNA plugin available for Ion
Torrent sequencing platforms that used the Torrent Mapping Alignment Program
(TMAP). TMAP first identify a list of Candidate Mapping Locations (CMLs) and
aligned with Smith Waterman algorithm for specific and sensitive mapping. DEG
analysis was performed using R/Bioconductor package DESeq2, with read count
normalized to produce differential gene expressions as determined by p-value and
the log2 fold change. GEO superSeries: GSE129027.
Comet assay. Comet assay was performed using OxiSelect 96-well kit (Cell Bio-
labs, #STA-355) according to manufacturer’s recommendation. Briefly, treated cells
were trypsinized and mixed with low melting-point agarose at 37 °C. Cells/agarose
mixture was quickly placed onto pre-coated 96-well Comet slide, and cooled at 4 °C
to solidify the agarose layer. The ready slide was treated with hypertonic lysis
buffer, and followed by incubation with alkaline buffer to unwind DNA strands
and expose the alkali labile sites (comet tails), which were imaged by fluorescence
microscopy at ×20 magnification (Olympus IX71/DP71). Olive Tail Moment
(OTM) was quantified using ImageJ software (NIH, 1.51n) with OpenComet
plugin, using the formula OTM = (mean Tail-Intensity – mean Head-Intensity) X
Tail%DNA/100. The mean ± S.D. of OTM from at least 50 cells in each treatment
group was quantified.
Nuclear NFĸB activity assay. Activation of nuclear NFĸB p65 subunit was
quantified in nuclear protein extracts using the ELISA-based TransAM p65 NF-kB
Kit (Active Motif, #40596) according to manufacturer’s recommendation. Cellular
fractionation was performed as described, and absorbance measurements (450 nm)
on nuclear extracts (5 µg) in triplicates were performed using TECAN Infinite plate
reader.
High-content microscopy and immunofluorescence imaging. Cultured cells
were fixed with methanol for 30 min, and immunostained with acetyl-p53 (1:500,
Cell Signaling, #2570), p-p53 (1:500, Cell Signaling, #9286), or NF-κB p65 (1:1000,
Cell Signaling, #8242) for 4 hours at 4 °C, followed by incubation with Alexa Fluor-
488 or −594 secondary antibodies (1:1000, Molecular Probes, Life Technologies,
A11034 and R37121) for 2 h at 25 °C, and by Hoechst 33342 nuclear staining
(1:2000, Sigma, #23491-52-3) for 15 min. Imaging of 96-well plate was performed
using a high-content imaging system (MetaXpress Ultra, Molecular Devices) with
×40 objective. Airyscan super-resolution confocal images were acquired with
LSM800 (Zeiss Germany) with ×63 objective. Image analyses were conducted using
the Color Deconvolution Plugin in ImageJ software (NIH; 1.51n)69.
Tumor xenograft assay. All in vivo xenograft studies adhered to the SingHealth
Animal Care and Use Committee (IACUC) guidelines on animal use and handling.
Usage of patient-derived materials have been approved by SingHealth Institutional
Review Board (IRB). All tumor xenografts were established in male C.B-17 SCID
mice aged 9-10 weeks and weighed 23–25 g (InVivos Pte. Ltd., Singapore). Mice
were provided with sterilized food and water ad libitum, and housed in negative
pressure isolators, which were set at 23 °C and 43% humidity, with 12-h light/dark
cycles.
In brief, 10 × 106 isogenic Calu-1 cells (empty vector control, wtp53, mutp53) in
100 µL of PBS or 1–2 mm3 dices of PDX tumors (GC-PDX and HCC-PDX) were
injected subcutaneously into the flanks of each mice. Tumor size was monitored
and measured three times weekly with Vernier calipers (tumor volume= length ×
width2 × 3.14159/6). For inhibitor studies, mice were assigned into stratified groups
based on average tumor volume (n= 5 animals/10 tumors per group). Treatment
began when the tumor sizes reached ~200 mm3. Cisplatin was provided in 0.9%
NaCl and given at 4 mg kg−1 by intraperitoneal (ip), once weekly for 3 weeks. JQ1
and topotecan were formulated in 30% (w/v) Captisol and 30 % (w/v) PEG300 at
30 mg kg−1 and 1 mg kg−1, respectively, and given via PO (orally), 7 days a week.
Bodyweight at sacrifice and tumor samples were collected 3 weeks after treatment
commenced.
Immunohistochemistry (IHC), RNA in situ hybridization (ISH). Xenograft
tumors from control and compounds administered mice were fixed in formalin
after surgical excision overnight, and embedded in paraffin and sectioned (4 µm).
Tumor sections were deparaffinized using standard histologic procedures prior to
antigen retrieval. For IHC, slides were incubated with primary antibodies [NF-κB
p65 (1:1000, Cell Signaling, #8242), cleaved caspase 3 (1:1000, Cell Signaling,
#9661), Ki67 (1:1000, Abcam, #ab15580) overnight at 4 °C. Color development was
performed using EnVision+ System-HRP (DAB) kit (Dako, Agilent Technologies)
according to the manufacturer’s protocol. Single molecule mRNA ISH (RNAscope,
ACD Biotech) was performed using the Advanced Cell Diagnostics RNAscope 2.5
HD Detection kit (#322360) according to manufacturer’s recommendation. TRAIP
probe was customized. For both IHC and RNAscope, cell nuclei were counter-
stained with Hematoxylin (Thermo Scientific, #72604). Slide images were captured
under optical imaging microscope at ×20 magnification (Olympus IX71/DP71).
Images were acquired from five tumor samples each for every treatment group, and
analyzed with ImageJ software using an image processing workflow described
previously67. Briefly, Hematoxylin and DAB/Fast Red color-separated images were
derived from the original image using ImageJ Color Deconvolution plugin. Object
segmentation using the Particle Analyzer plugin was then performed to identify the
individual cellular regions in each image, and the signal intensity (DAB) or count
(Fast Red) in the image was then tabulated. IHC staining was analyzed as the
percentage of DAB-positive cells/100 cells in each slide image. RNA-ISH staining
was scored based on the number of positive signal in each cell (0: no staining or <1
dot/ 10 cells; 1: 1–3 dots/cell; 2: 4–9 dots/cell; 3: 10–15 dots/cell; 4: >15 dots/cell). At
least 20 images were analyzed for each tumor sample.
Statistics, data reporting, and reproducibility. No statistical method was applied
to predetermine sample size. All experiments were conducted three times unless
stated otherwise. Data that could be reproduced in biological replicates were
reported. Statistical analysis for the comparison between two groups was conducted
using Student’s t-test, while comparisons between multiple groups was conducted
using two-way ANOVA post-hoc tests.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The ChIP-seq and AmpliSeq datasets generated during the current study have been
deposited in GEO with the Accession number GSE129027 and could be accessed at this
link: https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE129027. All the other
data supporting the findings of this study are available within the article and its
supplementary information files and from the corresponding author upon reasonable
request. A reporting summary for this article is available as a Supplementary
Information file.
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